

1 **Title:** Direct detection of *Pseudomonas aeruginosa* from respiratory samples of children with
2 cystic fibrosis

3 **ABSTRACT**

4 **Introduction**

5 *Pseudomonas aeruginosa* is the most important cause of lung infection and major cause of
6 morbidity and mortality among Cystic Fibrosis patients. Early detection of *P. aeruginosa*
7 from clinical samples is a key element in patient management. Appropriate antimicrobial
8 treatment will postpone the transition to chronic lung infection.

9 **Methods**

10 Sputum and deep pharyngeal swab samples (DPS) of CF patients were inoculated into
11 conventional agar plates and identified by Matrix-assisted laser desorption/ionization-time of
12 flight mass spectrometry. DNA was extracted with a column based QIAamp DNA mini kit
13 from the samples. Molecular detection was done by using 23S rDNA specific primers with
14 Taqman probe for quantitative PCR (qPCR) and *exoA* gene specific primers for in house
15 PCR.

16 **Results**

17 A total number of 67 sputum and 33 DPS samples were included to the study. Median age of
18 the patients was 6 (2-14) for DPS and 15(7-33) for sputum samples. Detection limit was 10^3
19 cfu/ml for qPCR which displayed 94% sensitivity and 93% specificity for sputum; 44%
20 sensitivity and 100% specificity for DPS. In house PCR displayed 94% sensitivity and 93%
21 specificity for sputum; 50% sensitivity and 100% specificity for DPS. Time required for
22 conventional method was 48 hours , 6 hours for in- house PCR and 4 hours for qPCR.

23 **Conclusion**

24 Although culture is a reliable detection technique, a more rapid and sensitive way to detect *P.*
25 *aeruginosa* from CF airway samples is essential. In our study which culture is accepted as a
26 gold standard; PCR results is promising especially for sputum samples. Validation of

27 molecular methods is necessary before implementation in routine laboratories. Clinical
28 implications of discrepant results between culture and PCR detection should be carefully
29 evaluated and combining both approaches considering antibiotic treatment could be
30 reasonable.

31 **Keywords:** *Pseudomonas aeruginosa*, Cystic Fibrosis, *exoA*, *23S rDNA*, Real-Time
32 Polymerase Chain Reaction, Molecular Method, Culture Method

33 INTRODUCTION

34

35 Cystic Fibrosis (CF) is an autosomal recessive disease, caused by mutation in the
36 cystic fibrosis transmembrane conductance regulator (CFTR) gene which provides
37 instructions for making a protein called CFTR. This protein functions as a channel across the
38 membrane of the cell, plays an important role in the regulation of calcium activated chloride
39 ion channels, sodium bicarbonate and aquaporin channels, sodium, and potassium transitions.
40 Disease causing mutations in the CFTR gene alter the production, structure, and stability of
41 the chloride channel. All these changes prevent the channel from functioning properly, that
42 weakens the transport of chloride ions and the movement of water into and out of cells.
43 Therefore, epithelial cells of the lungs, pancreas, and other organs produce mucus that is
44 abnormally thick and sticky. Consequently, impaired mucus separation in the pericilliary
45 layer reduces the excretion of viscous lung secretions and facilitates infection and
46 colonization with bacteria. Abnormal mucus obstructs the airways and glands, leading to the
47 symptoms of CF [1].

48 *P. aeruginosa* is the main pathogen involved in the regression of lung function in CF
49 patients, can cause sepsis and acute infection, which can result in death, and a chronic
50 infection that can last for years [2]. During acute infection, it releases toxins into the
51 environment and damages the host tissue. Chronic infection is thought to be characterized by
52 the formation of a biofilm on the surface of the airways epithelial cells containing thick
53 mucus layer. These biofilms may be persistent despite aggressive antibiotic therapy [3-4].

54 According to the registered data of CF patients, *P. aeruginosa* is a predominant
55 microorganism isolated from the respiratory tract of adult CF patients, and its prevalence
56 increases to 20% in patients younger than 5 years old and up to 70% in patients aged 18 years.
57 Also, it was found that pulmonary function regressed more rapidly because of chronic lung
58 infection with *P. aeruginosa* and caused early death of CF patients [5].

59 The first age in which *P. aeruginosa* was found to be positive is defined as an
60 important predictor of prognosis. When *P. aeruginosa* is not eradicated properly children
61 have higher risk for subsequent exacerbations [1,5]. Emerson et al[6] states that the risk of
62 death in *P. aeruginosa* sputum culture positive patients with CF was 2.6 times higher and
63 early intervention may help to reduce the morbidity and mortality of young patients

64 Initial isolates of *P. aeruginosa* are generally not mucoid and are sensitive to
65 antibiotics. Therefore, early eradication has been shown to be effective in delaying chronic
66 and mucoid *P. aeruginosa* infection. The importance of the earliest possible detection in
67 sputum supports the consensus on the importance of the eradication of *P. aeruginosa* [7].

68 Current diagnostic techniques are based on culture-based approaches that are time-
69 consuming and subject to individual interpretation. A number of difficulties are encountered
70 with culture method. Firstly, microbiological culture may not be sufficient to detect pathogens
71 at low bacterial density or under antibiotic pressure. Secondly, *P. aeruginosa* may vary
72 phenotypically, which may lead to misidentification (small colony variants, loss of pigment
73 production, etc.). Third, *P. aeruginosa*, which produces biofilm, often prevents, or even
74 inhibits its isolation by closing other gram negative and positive bacteria in culture plates
75 under standard conditions [7].

76 In-house polymerase chain reaction (PCR) is one of the most popular methods for
77 detecting pathogens. It provides the detection of pathogens by targeting the nucleic acid
78 sequences of specific bacteria. PCR amplification products are stained with ethidium bromide
79 and visualized in bands on electrophoresis gel [8]. Real-time PCR or quantitative PCR
80 (qPCR) is a method that does not require agarose gel electrophoresis to detect amplified
81 products. This method can measure the fluorescence signal generated by the added dyes or
82 specific probes labeled at both ends, allowing the PCR products generated throughout the
83 reaction to be continuously monitored. The fluorescence intensity is proportional to the
84 amount of PCR amplicons [9].

85 The rapid detection of *P. aeruginosa* directly from clinical materials might be
86 important to improve the life quality of the CF patient by rapid and timely intervention of
87 colonization / infection. We analyzed the diagnostic value of two PCR methods from
88 respiratory samples by comparing conventional culture method.

89

90 MATERIALS and METHODS

91 Respiratory samples (sputum and DPS) used in this study were obtained from CF
92 patients followed in Marmara University Training and Research Hospital Chest Diseases
93 department, and sent to the microbiology laboratory for routine examinations. The study
94 protocol was approved by the Institutional Review Board and the Ethics Committee of
95 Faculty of Medicine, Marmara University. An equal volume of sputazole (Thermo Scientific,
96 USA) solution was added to the sputum samples and homogenized in a shaker incubator for 1
97 hour at 37 °C [10]. During the process, the samples were vortexed every 15 minutes. The
98 resulting homogenates were transferred to 1,5 ml volume Eppendorf tubes for DNA
99 extraction. DPS samples were processed directly.

100 Samples were initially screened by Gram staining and were inoculated further when
101 > 25 leukocyte but >10 SEC per low power field. MacConkey plates, 5% sheep-blood agar
102 plates (BioMerieux, France), and *Haemophilus* selective agar (chocolate agar including
103 bacitracin) plates were used and plates were incubated for minimum 24 hours at 35,5 °C. If
104 growth of colonies on petri plates are not sufficient for identification, they are allowed to
105 incubate for up to 72 hours. After incubation, colonies formed in the agar plates were
106 identified at the species level by Matrix-assisted laser desorption/ionization-time of flight
107 mass spectrometry (MALDI-TOF MS) (BioMerieux, France). The results of studied samples
108 by MALDI-TOF MS are obtained after approximately 30 minutes. *P. aeruginosa* 27853
109 ATCC strain was used for quality control.

110 DNA extraction was done with a column based QIAamp DNA mini kit (QIAGEN),
111 following the manufacturer's instructions. Proteinase K treatment step in the procedure was
112 performed at 56 °C for 3 hours. DNA of sputum samples was eluted in 200µl of elution
113 buffer; DNA of DPS samples was eluted in 100µl of elution buffer and stored in -80°C.
114 Following DNA extraction, quality of total DNA was determined using 1% agarose gel
115 electrophoresis.

116

117 In-house PCR was done targeting the *exoA* gene with *P. aeruginosa* specific primers
118 (*exoA*-F-5'-GAC AAC GCC CTC AGC ATC ACC AGC-3'; *exoA*-R-5'-CGC TGG CCC ATT
119 CGC TCC AGC GCT-3'), previously described by Xu et al [11]. The reaction mix comprised
120 2,5µl of 10Xbuffer, 2,5µl of MgCl₂, 0,5µl of each primers, 1µl of 10mM dNTP, 0,5µl of

121 DNA polymerase, 1µl (50-100ng) of DNA extract and the final reaction volume was
122 completed to 25µl with free DNA water. Program consisted of 96°C for 5 min followed by 40
123 cycles of 96°C for 1 min, 55°C for 1 min, 72°C for 1 min, followed by a final extension at
124 72°C for 10 min. Visualization of in-house PCR products were performed by 1% agarose gel
125 electrophoresis and ethidium bromide staining.

126

127 Quantitative PCR (qPCR) amplification was done using *P. aeruginosa* specific
128 primers targeting the *23S rDNA* (Pa23F-5'-*TCC AAG TTT AAG GTG GTA GGC TG*-3' and
129 Pa23R-5'-*ACC ACT TCG TCA TCT AAA AGA CGA C*-3') and Taqman probe (Pa23P-6-
130 FAM-*AGG TAA ATC CGG GGT TTC AAG GCC*-TAMRA) as previously described by
131 McCulloch et al [12]. Probe and primers specific to *GADPH* gene was used as an endogenous
132 control (IPC-F- 5' *ACT CCT TTT GCA GAC CAC AG* 3'; IPC-R-5' *CAG TAG AGG CAG*
133 *GGA TGA TG* 3'; IPC-Prob-5'-Yakima Yellow-*ATG CCA TCA CTG CCA CCC AGA*-BHQ-
134 1-3'). The reaction mix comprised 10µl of 2XTaqMan Master mix, 0,8µl of each primers (for
135 both of *23S rDNA* and endogenous control), 0,4µl of each prob (for both of *23S rDNA* and
136 endogenous control) and, 1µl (50-100ng) of DNA extract and was made up to a final reaction
137 volume of 20µl with free DNA water. The qPCR program consisted of 50 °C for 2 min, 95 °C
138 for 15 min and 40 cycles of 95 °C for 15 s and 60 °C for 1 min with a plate read after every
139 cycle. The amplification efficiency and sensitivity range of PCR assays improved were
140 demonstrated by amplifying aliquots of 10-fold serial dilutions (10^8 to 10^2) from DNA of *P.*
141 *aeruginosa* 27853 ATCC strain.

142

143 **RESULTS**

144 A total number of 67 sputum and 33 DPS samples from children with CF were
 145 included to the study. Median age was 6 (2-14) for DPS and 15(7-33) for sputum samples. In
 146 33 of 35 sputum samples, culture and molecular methods were positive when two samples
 147 were positive for both PCR methods when the culture was negative (Table 1).

148

149 **Table1.** The comparison of PCR and culture results for sputum samples

Sputum	<i>exoA</i> positive	<i>exoA</i> negative	<i>23S</i> positive	<i>rDNA</i> <i>23S</i> <i>rDNA</i> negative
Culture positive	33	2	33	2
Culture negative	2	30	2	30
Total	35	32	35	32

150

151 In house PCR was negative in 9 and qPCR was negative in 10 of 15 culture positive DPS
 152 samples (Table 2).

153

154 **Table2.** The comparison of PCR and culture results for DPS samples.

DPS	<i>exoA</i> positive	<i>exoA</i> negative	<i>23S rDNA</i> positive	<i>23S rDNA</i> negative
Culture positive	9	9	8	10
Culture negative	0	15	0	15
Total	9	24	8	25

155

156

157

158

159

160 When the culture was taken as the gold standard, sensitivity and specificity for both PCR
 161 methods were 93-94% in sputum samples. However, we were not able to amplify targeted
 162 genes by both PCR methods in half of culture positive DPS samples and detection
 163 sensitivities were found very low (Table 3).

164

165 **Table 3.** Evaluation of results in-house and qPCR when the culture is taken as the gold
 166 standard.

		Sensitivity	Specificity	Positive predictive value	Negative predictive value
qPCR	Sputum	94%	93%	94%	93%
	DPS	44%	100%	100%	60%
In-house PCR	Sputum	94%	93%	94%	93%
	DPS	50%	100%	100%	62%

167

168

169 The time required for in-house PCR analysis, including DNA isolation,
 170 amplification, and gel electrophoresis for imaging, took approximately 6 hours whereas
 171 results were obtained in 3-4 hours by qPCR. Isolation and identification of *P. aeruginosa* in
 172 culture plates took between 24 and 48 hours, in cases requiring further incubation it took up to
 173 72 hours.

174

175 **DISCUSSION**

176 While PCR amplification has been routinely used for diagnosis of viral infections
177 directly from clinical samples it is not very common for bacterial infections. Early detection
178 of *P. aeruginosa* will lead to a rapid and timely intervention to colonization/infection, leading
179 to an increase of quality of life of the CF patients. Deschaght et al. performed a nationwide
180 study a decade ago and stated that both routine culture techniques and DNA amplification
181 techniques perform equally well in detection of *P. aeruginosa* in respiratory samples of CF
182 patients [13]. For a total of 852 samples, 26 samples were negative by culture but positive by
183 qPCR, and 10 samples were positive by culture but remained negative by qPCR. Authors
184 concluded that qPCR may have a predictive value for impending *P. aeruginosa* infection for
185 only a limited number of patients.

186 The sampling method strongly influence the sensitivity of infection diagnosis. Any
187 definition of first life time/early/new as well as chronic *P. aeruginosa* infection should clearly
188 describe sampling frequency [14]. Using multiple target genes improves the sensitivity of the
189 method by eliminating false negative and false positive results. Sensitivity is not an issue
190 when the bacterial load is high, but in low concentrations as may be found in recently
191 colonized patients it is very important since early detection is crucial. In our study, we were
192 not able to amplify targeted genes by both of PCR methods in half of culture positive DPS
193 samples. This might be interpreted as insufficient bacterial presence and consequently
194 insufficient DNA for PCR. According to a similar study of Xu et al. targeting *exoA* target
195 gene, discrepancy in the detection of PCR and culture of *P. aeruginosa* is based on a number
196 of factors including phenotypic misidentification and auxotrophic mutations [11]. In the study
197 of McCulloch et al. the sensitivity value was 100% and the specificity was 52% [12]. Based
198 on the results of a similar study by Logan et al., these data suggest that PCR may have a
199 potential to detect *P. aeruginosa* earlier, but that the presence of the organism can be reliably
200 reported using a combined approach of culture and molecular techniques [15]. Boutin et al.
201 focused on the superiority of molecular techniques over culture technique which is considered
202 the gold standard and observed a good sensitivity of the qPCR (>95% in sputum and >90% in
203 the throat swabs) but specificity was low (83.9% in sputum and 78.6% in the throat swabs).
204 Their results show that the discriminative power of qPCR was interpreted as high in sputum
205 samples and low in throat swabs [16]. Low discriminative power of qPCR in throat swabs was
206 mostly due to the low bacterial burden observed in this material However, Heltshe et al.

207 stated that pharyngeal culture technique results might not be generalizable to lower airway *P.*
208 *aeruginosa* since pharyngeal cultures have poor sensitivity and positive predictive value for
209 the presence of *P. aeruginosa* [17].

210 We detected the presence of *P. aeruginosa* in 6 hours by in-house PCR and 4 hours by
211 qPCR. A patient who gives a sample in the morning will be able to get the results during the
212 day and the doctor will have the opportunity to start treatment immediately. This is a potential
213 advantage for clinicians in order to reduce the exacerbations with early diagnosis and
214 treatment applications of infection by *P. aeruginosa* in CF patients. It is not known whether it
215 is reasonable and acceptable to recommend a therapeutic intervention based on a PCR result
216 without antibiotic susceptibility data. However, early detection by PCR has the potential to
217 increase the levels of awareness of the upcoming infection. It is also important to monitor
218 such patients who exhibit PCR positive / culture negative findings from their sputum, to
219 determine if there are transient infections of cases that do not result in established
220 colonization leading to chronic infection. In addition, it is important to monitor patients with
221 such a PCR positive / culture negative result in terms of optimal antibiotic management and
222 infection.

223

224 **Conclusion:** Progressive loss of pulmonary functions related persistent colonization of *P.*
225 *aeruginosa* is a big challenge for clinicians and rapid and sensitive detection of *P. aeruginosa*
226 is the major point of patient management. If equipment is available in routine laboratories ,
227 PCR which is applied directly from clinical materials could be used for the fastest results .
228 Early PCR detection might facilitate patient screening however it is reasonable to advise
229 therapy based on susceptibility data.

230

231

232 **REFERENCES**

- 233 1. Talwalkar JS, Murray TS. The approach to *Pseudomonas aeruginosa* in cystic
234 fibrosis. *Clin Chest Med* 2016;37:69-81
- 235 2. Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung
236 environment and *Pseudomonas aeruginosa* infection. *BMC Pulm Med* 2016;16:174
- 237 3. Jansen G, Mahrt N, Tueffers L, et al. Association between clinical antibiotic resistance
238 and susceptibility of *Pseudomonas* in the cystic fibrosis lung. *Evol Med Public*
239 *Health* 2016;2016:182-194
- 240 4. Jørgensen KM, Wassermann T, Johansen HK, et al. Diversity of metabolic profiles of
241 cystic fibrosis *Pseudomonas aeruginosa* during the early stages of lung
242 infection. *Microbiol* 2015;161:1447-1462
- 243 5. Ehsan Z, Clancy JP. Management of *Pseudomonas aeruginosa* infection in cystic fibrosis
244 patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. *Future*
245 *Microbiol* 2015;10:1901-1912
- 246 6. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. *Pseudomonas aeruginosa*
247 and other predictors of mortality and morbidity in young children with cystic fibrosis.
248 *Pediatr Pulmonol* 2002;34:91-100
- 249 7. Hery-Arnaud G, Nowak E, Caillon J, et al. Evaluation of quantitative PCR for early
250 diagnosis of *Pseudomonas aeruginosa* infection in cystic fibrosis: a prospective cohort
251 study. *Clin Microbiol Infect* 2017;23:203-207
- 252 8. Alahi MEE, Mukhopadhyay SC. Detection Methodologies for Pathogen and Toxins: A
253 Review. *Sensors* 2017;17(8):1885
- 254 9. Deschaght P, De Baere T, Van Simaey L, et al. Comparison of the sensitivity of culture,
255 PCR and quantitative real-time PCR for the detection of *Pseudomonas aeruginosa* in
256 sputum of cystic fibrosis patients. *BMC Microbiol* 2009;9:244
- 257 10. Xu J, Moore JE, Murphy PG, Millar BC, Elborn JS. Early detection of *Pseudomonas*
258 *aeruginosa*—comparison of conventional versus molecular (PCR) detection directly from
259 adult patients with cystic fibrosis (CF). *Ann Clin Microbiol Antimicrob* 2004;3:21
- 260 11. McCulloch E, Lucas C, Ramage G, Williams C. Improved early diagnosis of
261 *Pseudomonas aeruginosa* by real-time PCR to prevent chronic colonisation in a paediatric
262 cystic fibrosis population. *J Cyst Fibros* 2011;10:21-24

- 263 12. Deschaght P, Schelstraete P, Lopes dos Santos Santiago G, et al. Comparison of culture
264 and qPCR for the detection of *Pseudomonas aeruginosa* in not chronically infected cystic
265 fibrosis patients. *BMC Microbiol* 2010;10:245
- 266 13. Taccetti, G., Denton, M., Hayes, K., ECFS-CTN Microbiology Group, Drevinek, P.,
267 Sermet-Gaudelus. A critical review of definitions used to describe *Pseudomonas*
268 *aeruginosa* microbiological status in patients with cystic fibrosis for application in
269 clinical trials. *J Cyst Fibros* 2020;19:52-67
- 270 14. Logan C, Habington A, Lennon G, Cronin F, O'Sullivan N. Evaluation of the efficacy of
271 real-time polymerase chain reaction for the routine early detection of *Pseudomonas*
272 *aeruginosa* in cystic fibrosis sputum and throat swab specimens. *Diagn Microbiol Infect*
273 *Dis* 2010;68:358-365
- 274 15. Boutin S, Weitnauer M, Hassel S, et al. One-time quantitative PCR detection of
275 *Pseudomonas aeruginosa* to discriminate intermittent from chronic infection in cystic
276 fibrosis. *J Cyst Fibros* 2018;17:348-355
- 277 16. Heltshe SL, Khan U, Beckett V, et al. Longitudinal development of initial, chronic and
278 mucoid *Pseudomonas aeruginosa* infection in young children with cystic fibrosis. *J Cyst*
279 *Fibros* 2018;17:341–347
- 280 17. Saiman L, Burns JL, Larone D, Chen Y, Garber E, Whittier S. Evaluation of MicroScan
281 Autoscan for identification of *Pseudomonas aeruginosa* isolates from cystic fibrosis
282 patients. *J Clin Microbiol* 2003;41:492-4

283

284 **DECLARATIONS**

285 **Funding:** This study was supported by a grant from Marmara University, grant number:
286 SAG-C-YLP-070317-0093

287 **Conflicts of interest:** The authors declare that there are no conflicts of interest.

288 **Ethical Approval:** In this research, we do not have unethical behavior at any stage from
289 planning to writing, we have obtained all the information in the study within academic and
290 ethical rules, we have cited all the information and comments not obtained with this study and
291 we have included these sources in the list of references, we declare that there is no violation
292 of patent and copyright rights during the work.

293 **Consent to participate:** Available

294 **Consent for publication:** Available

295 **Code availability:** Not available

296